Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Delayed Data from NSDQ)

$4.19 USD

4.19
1,145,261

0.00 (0.00%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $4.18 -0.01 (-0.24%) 5:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ironwood Begins New Phase III Study to Expand Linzess Label

by Zacks Equity Research

Ironwood (IRWD) commences a phase IIIb study in order to add a couple of new symptoms like bloating and discomfort associated with IBS-C to Linzess' label.

    Ironwood Initiates Phase III Studies on Reflux Candidate

    by Zacks Equity Research

    Ironwood (IRWD) initiates two phase III studies on its gastrointestinal candidate, IW-3718, to evaluate it in persistent gastroesophageal reflux disease.

      Ironwood Pharmaceuticals (IRWD) Down 10.3% Since Earnings Report: Can It Rebound?

      by Zacks Equity Research

      Ironwood Pharmaceuticals (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring

        by Zacks Equity Research

        Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the first quarter. The company will be separated into two entities for better management.

          Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up

          by Zacks Equity Research

          Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the fourth quarter. Demand for Linzess continues to rise.

            Ironwood Succeeds in Diabetic Hypertension Phase II Study

            by Zacks Equity Research

            Ironwood Pharmaceuticals' (IRWD) pipeline candidate, IW-1973, reduces blood pressure and improves metabolic parameters in type II diabetes with hypertension patients in a phase IIa study.

              Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up

              by Zacks Equity Research

              Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the third quarter. Demand for Linzess rises.

                Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up

                by Zacks Equity Research

                Ardelyx's (ARDX) tenapanor reduces abdominal pain and improves bowel movements in a phase III study evaluating the drug in irritable bowel syndrome with constipation.

                  Why Is Ironwood (IRWD) Down 4.1% Since the Last Earnings Report?

                  by Zacks Equity Research

                  Ironwood (IRWD) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Ironwood Pharma's Combination Gout Drug Gets FDA Approval

                    by Zacks Equity Research

                    Ironwood Pharmaceuticals, Inc. (IRWD) announced that the FDA has approved Duzallo for the treatment of hyperuricemia in patients with uncontrolled gout.

                      Ironwood (IRWD) Q2 Loss Widens, Revenues Miss, Stock Up

                      by Zacks Equity Research

                      Ironwood Pharmaceuticals' (IRWD) second-quarter results were dismal, missing sales and earnings estimates.

                        Ironwood (IRWD) Reports Positive Data on Reflux Candidate

                        by Zacks Equity Research

                        Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease.

                          Allergan Reports Positive New Data on Irritable Bowl Drug

                          by Zacks Equity Research

                          Allergan plc (AGN) has announced positive data from a pooled analysis of two phase III studies, evaluating its marketed drug Viberzi (eluxadoline) for treatment of adults suffering from irritable bowel syndrome with diarrhea (IBS-D).

                            Why Is Ironwood (IRWD) Up 6.9% Since the Last Earnings Report?

                            by Zacks Equity Research

                            Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                              Allergan's Irritable Bowel Drug Viberzi Approved in Canada

                              by Zacks Equity Research

                              Allergan plc (AGN) announced that Health Canada approved Viberzi (eluxadoline) for the treatment of adults suffering with irritable bowel syndrome with diarrhea (IBS-D)

                                Ironwood (IRWD) Q1 Loss Wider than Expected, Sales Miss

                                by Zacks Equity Research

                                Ironwood Pharmaceuticals, Inc. (IRWD) reported first-quarter 2017 adjusted loss of 33 cents per share, significantly wider than both the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 8 cents.

                                  Are Options Traders Betting on a Big Move in Ironwood Pharmaceuticals (IRWD) Stock?

                                  by Zacks Equity Research

                                  Huge implied volatility makes Ironwood Pharmaceuticals (IRWD) Stock lucrative to the option traders.

                                    Ironwood (IRWD) Q4 Loss Narrower than Expected; Sales Top

                                    by Zacks Equity Research

                                    Ironwood Pharmaceuticals, Inc. (IRWD) reported an adjusted loss of 12 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 23 cents but slightly wider than the year-ago loss of 11 cents.

                                      Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS

                                      by Zacks Equity Research

                                      Here we have three pharma companies that are set to report fourth-quarter results on Feb 21. Let's see how things are shaping up for this quarter.

                                        Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?

                                        by Zacks Equity Research

                                        Radius Health, Inc. (RDUS) is scheduled to report fourth-quarter 2016 financial results on Feb 23.

                                          Arpita Dutt headshot

                                          5 Drug Stocks Poised to Beat Earnings Estimates in Q4

                                          by Arpita Dutt

                                          Medical is one of the few sectors that has consistently recorded earnings growth over the last 4 quarters. Here is a look at 5 pharma and biotech stocks that look set to beat Q4 earnings estimates.

                                            Ironwood/Astellas Report Positive Phase III Data on Linzess

                                            by Zacks Equity Research

                                            Ironwood (IRWD) and partner Astellas reported positive top-line data from a phase III study on Linzess in adults with chronic constipation.

                                              Ironwood-Allergan Linzess Gets FDA Approval in Lower Dose

                                              by Zacks Equity Research

                                              Ironwood Pharmaceuticals, Inc. (IRWD) and partner Allergan plc (AGN) announced that the FDA has approved a lower dose strength of Linzess (linaclotide) ??? 72 mcg ??? for the treatment of adult patients with chronic idiopathic constipation (CIC).

                                                Ironwood, Allergan Report Positive Linzess IBS-C Study Data

                                                by Zacks Equity Research

                                                Ironwood (IRWD) and Allergan (AGN) report phase IIb study data on colonic release formulations of Linzess for the treatment of irritable bowel syndrome with constipation.